Overview

* MediWound Q2 2025 revenue rises 43% sequentially, beating analysts' expectations

* Net loss widens to $13.3 mln, driven by non-cash financial expenses

* Co establishes strategic research collaborations with Essity and Convatec for EscharEx trials

Outlook

* Company expects full operational capacity for NexoBrid by year-end 2025

* Company received $3.6 mln from U.S. DoD for NexoBrid development

* MediWound ( MDWD ) continues EscharEx Phase III trial enrollment with new partnerships

Result Drivers

* NEXOBRID ADOPTION - U.S. adoption of NexoBrid continues to grow, with Vericel reporting 52% year-over-year revenue growth

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $5.70 $5.68

Revenue mln mln (6

Analysts

)

Q2 EPS -$1.23

Q2 Net -$13.30

Income mln

Q2 Miss -$4.50 -$4.25

Adjusted mln mln (2

EBITDA Analysts

)

Q2 Gross $1.30

Profit mln

Q2 -$5.70

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy"

* Wall Street's median 12-month price target for Mediwound Ltd ( MDWD ) is $30.50, about 38.5% above its August 13 closing price of $18.75

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)